The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
The investment in land is Rs. 19.85 crore
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
The inspection was concluded with zero observations
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
Subscribe To Our Newsletter & Stay Updated
